796848-80-1

Basic information

• Product Name: phenyl 2-chloro-4-hydroxyphenylcarbaMate
• Synonyms: phenyl 2-chloro-4-hydroxyphenylcarbaMate;(2-Chloro-4-hydroxy-phenyl)-carbamic acid phenyl ester;phenyl N-(2-chloro-4-hydroxyphenyl)carbamate;Carbamic acid, (2-chloro-4-hydroxyphenyl)-, phenyl ester;lenvaint-H
• CAS NO: 796848-80-1
• Molecular Formula: C₁₃H₁₀ClNO₃
• Molecular Weight: 263.6764
• EINECS: -0
• Mol File: 796848-80-1.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 392.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.426±0.06 g/cm3(Predicted)
• PKA: 9.07±0.31(Predicted)
• CAS DataBase Reference: phenyl 2-chloro-4-hydroxyphenylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl 2-chloro-4-hydroxyphenylcarbaMate(796848-80-1)
• EPA Substance Registry System: phenyl 2-chloro-4-hydroxyphenylcarbaMate(796848-80-1)

Safety Data

• Hazardous Substances Data: 796848-80-1(Hazardous Substances Data)

Usage

Uses

Phenyl N-?(2-?Chloro-?4-?hydroxyphenyl)?carbamate is a reagent used in the prepartion of quinoline-carboxamide compounds including Lenvatinib (L329400), an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

Upstream product

• 1885-14-9 phenyl chloroformate 
• 17609-80-2 4-amino-3-chlorophenol 

Downstream Products

• 417716-92-8 lenvatinib 
• 796848-79-8 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropyl urea 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF LENVATINIB

The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.

Isotope enrichment lenvatinib

The invention discloses isotope enrichment lenvatinib, a pharmaceutically acceptable salt form thereof, and a treatment method using the isotope enrichment lenvatinib, and specifically relates to an isotope enrichment compound represented by a formula I o

Substituted urea compound and pharmaceutically acceptable salts or solvates thereof, application for substituted urea compound and pharmaceutically acceptable salts or solvates of substituted urea compound, and pharmaceuticals and pharmaceutical compositi

The invention provides a substituted urea compound, and pharmaceutically acceptable salts or solvates thereof. The invention also provides an application of the substituted urea compound, the pharmaceutically acceptable salts or the solvates of the substi